In response to The Medical Device User Fee Amendments of 2012 (MDUFA III),which authorizes FDA to collect user fees for the review of certain premarket submissions, FDA proposed process improvements to provide further transparency to the review process and to update the Agency’s approach to the Interactive Review to reflect FDA’s commitments in the MDUFA III Commitment Letter.  The updates are described in the draft guidance released on March 5, 2013 titled Types of Communication During the Medical Device Submissions.